Fatty Liver

Metabolic Diseases
6
Pipeline Programs
6
Companies
5
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
0
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 4 programs with unclassified modality

On Market (2)

Approved therapies currently available

U
METFORMIN HYDROCHLORIDEApproved
metformin
Unknown Company
oral2018
U
XENICALApproved
orlistat
Unknown Company
Intestinal Lipase Inhibitor [EPC]oral1999

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
OrlistatPhase 4Small Molecule1 trial
Active Trials
NCT00160407Completed50Est. Dec 2006
Pfizer
PfizerNEW YORK, NY
1 program
1
atorvastatinPhase 4Small Molecule1 trial
Active Trials
NCT01720719Unknown120Est. Dec 2016
M&
Merck & Co.RAHWAY, NJ
1 program
1
metforminPhase 2/31 trial
Active Trials
NCT00303537Unknown90Est. Jun 2008
One Biosciences
One BiosciencesFrance - Paris
1 program
1
AramcholPhase 21 trial
Active Trials
NCT02279524CompletedEst. May 2018
GS
Gilead SciencesFOSTER CITY, CA
2 programs
ELF TestN/A1 trial
ELF TestN/A
Active Trials
NCT05370053Unknown450Est. Dec 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Pfizeratorvastatin
RocheOrlistat
Merck & Co.metformin
One BiosciencesAramchol
Gilead SciencesELF Test

Clinical Trials (5)

Total enrollment: 710 patients across 5 trials

NCT01720719Pfizeratorvastatin

Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease

Start: May 2013Est. completion: Dec 2016120 patients
Phase 4Unknown

Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)

Start: Oct 2003Est. completion: Dec 200650 patients
Phase 4Completed

Metformin in Non-Alcoholic Fatty Liver Disease

Start: Nov 2004Est. completion: Jun 200890 patients
Phase 2/3Unknown

A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH

Start: Apr 2015Est. completion: May 2018
Phase 2Completed

The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology

Start: Sep 2020Est. completion: Dec 2022450 patients
N/AUnknown

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

6 companies competing in this space